DUBLIN--(BUSINESS WIRE)--The "Pneumonia Therapeutics Market Analysis By Product (Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy) And Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.
The global pneumonia therapeutics market is expected to reach USD 22.9 billion by 2025
This market is anticipated to grow at an unprecedented rate owing to the increasing prevalence of pneumococcal disease globally. The increasing demand for pneumonia therapeutics is a result of unmet clinical needs in emerging as well as developed regions.
Increasing focus of healthcare organizations on raising awareness and issuing guidelines for efficient management of pneumococcal disease is predicted to broaden the scope for growth over the coming years. For instance, Infectious Diseases Society of America/American Thoracic Society has issued guidelines on the management of community-acquired pneumonia.
Moreover, growing R&D activities in life sciences are anticipated to create positive impact on the market over the coming years. Consequentially, increase in number of products, currently being reviewed under clinical trials, is anticipated to fuel the overall growth. In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial.
The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and community-acquired bacterial pneumonia.
Key Topics Covered:
1 Methodology and Scope
2. Executive Summary
3. Pneumonia Therapeutics Market Variables, Trends & Scope
4. Pneumonia Therapeutics Market: Product Estimates & Trend Analysis
5. Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis, by Product
6. Competitive Landscape
- Pfizer, Inc.
- Bayer AG
- Merck & Co., Inc.
- Novartis AG
- GlaxoSmithKline plc
- Lupin Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/ksrzkc/pneumonia